Patients with intracerebral hemorrhage (ICH) who were treated with the recombinant hemostatic agent NovoSeven showed a significant reduction in hematoma growth, compared with those taking placebo. These results were from the largest clinical trial ever conducted on drugs used to treat ICH. Patients in the NovoSeven group showed improved neurologic and functional outcome, which led researchers to believe that there was a lasting benefit in terms of reduced disability and dependency on help.
In North America, Europe, and Japan, there are approximately 250,000 people who have experienced ICH (hemorrhagic stroke), which is the least treatable form of stroke. These patients face severe disability and high mortality. Until the NovoSeven study, there had been no proven treatment for ICH, and NovoSeven had been used primarily for treating bleeding episodes in hemophilia patients.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs